Exodus Point Capital Management, LP Kodiak Sciences Inc. Transaction History

Exodus Point Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$6.52 - $8.05 $1.1 Million - $1.36 Million	-168,837 Reduced 62.21%	102,574 $734,000
Q3 2022 Nov 10, 2022	BUY	$7.57 - $12.5 $1.91 Million - $3.16 Million	252,480 Added 1333.69%	271,411 $2.1 Million
Q2 2022 Aug 19, 2022	SELL	$5.04 - $9.48 $315,917 - $594,225	-62,682 Reduced 76.8%	18,931 $145,000
Q1 2022 May 13, 2022	BUY	$7.09 - $89.45 $578,636 - $7.3 Million	81,613 New	81,613 $630,000
Q1 2021 May 17, 2021	SELL	$110.45 - $164.47 $542,419 - $807,712	-4,911 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$60.78 - $154.03 $405,645 - $1.03 Million	-6,674 Reduced 57.61%	4,911 $721,000
Q3 2020 Nov 16, 2020	BUY	$45.05 - $59.27 $521,904 - $686,642	11,585 New	11,585 $686,000

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $303M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.